LCZ696, an Angiotensin Receptor-Neprilysin Inhibitor, Improves Cardiac Hypertrophy and Fibrosis and Cardiac Lymphatic Remodeling in Transverse Aortic Constriction Model Mice
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
LCZ696, an Angiotensin Receptor-Neprilysin Inhibitor, Improves Cardiac Hypertrophy and Fibrosis and Cardiac Lymphatic Remodeling in Transverse Aortic Constriction Model Mice
Authors
Keywords
-
Journal
Biomed Research International
Volume 2020, Issue -, Pages 1-10
Publisher
Hindawi Limited
Online
2020-01-12
DOI
10.1155/2020/7256862
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Inhibition of lymphatic proliferation by the selective VEGFR-3 inhibitor SAR131675 ameliorates diabetic nephropathy in db/db mice
- (2019) Seun Deuk Hwang et al. Cell Death & Disease
- LCZ696, an angiotensin receptor-neprilysin inhibitor, ameliorates diabetic cardiomyopathy by inhibiting inflammation, oxidative stress and apoptosis
- (2019) Qing Ge et al. EXPERIMENTAL BIOLOGY AND MEDICINE
- LCZ696 (Sacubitril/Valsartan), an Angiotensin-Receptor Neprilysin Inhibitor, Attenuates Cardiac Hypertrophy, Fibrosis, and Vasculopathy in a Rat Model of Chronic Kidney Disease
- (2018) Yasunori Suematsu et al. JOURNAL OF CARDIAC FAILURE
- Effect of LCZ696, a dual angiotensin receptor neprilysin inhibitor, on isoproterenol-induced cardiac hypertrophy, fibrosis, and hemodynamic change in rats
- (2018) Toru Miyoshi et al. Cardiology Journal
- LCZ696 improves cardiac function via alleviating Drp1-mediated mitochondrial dysfunction in mice with doxorubicin-induced dilated cardiomyopathy
- (2017) Yan Xia et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- Selective Stimulation of Cardiac Lymphangiogenesis Reduces Myocardial Edema and Fibrosis Leading to Improved Cardiac Function Following Myocardial InfarctionCLINICAL PERSPECTIVE
- (2016) Orianne Henri et al. CIRCULATION
- LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice
- (2016) Yasunori Suematsu et al. EUROPEAN JOURNAL OF HEART FAILURE
- LCZ696, Angiotensin II Receptor-Neprilysin Inhibitor, Ameliorates High-Salt-Induced Hypertension and Cardiovascular Injury More Than Valsartan Alone
- (2015) Hiroaki Kusaka et al. AMERICAN JOURNAL OF HYPERTENSION
- Ischemia-Reperfusion Injury Enhances Lymphatic Endothelial VEGFR3 and Rejection in Cardiac Allografts
- (2015) A. Dashkevich et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Cardiac lymphatics are heterogeneous in origin and respond to injury
- (2015) Linda Klotz et al. NATURE
- Cytokines are systemic effectors of lymphatic function in acute inflammation
- (2013) Melissa B. Aldrich et al. CYTOKINE
- The potential role of valsartan + AHU377 (LCZ696) in the treatment of heart failure
- (2013) Adriaan A Voors et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial
- (2012) Scott D Solomon et al. LANCET
- Regulation and implications of inflammatory lymphangiogenesis
- (2012) Honsoul Kim et al. TRENDS IN IMMUNOLOGY
- LYVE-1 upregulation and lymphatic invasion correlate with adverse prognostic factors and lymph node metastasis in neuroblastoma
- (2012) Pramila Ramani et al. VIRCHOWS ARCHIV
- Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual-Acting Angiotensin Receptor-Neprilysin Inhibitor (ARNi)
- (2009) Jessie Gu et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Characterization of the inflammatory and fibrotic response in a mouse model of cardiac pressure overload
- (2008) Ying Xia et al. HISTOCHEMISTRY AND CELL BIOLOGY
- Lymphangiogenesis and lymph node metastasis in breast cancer
- (2008) Giles H Cunnick et al. Molecular Cancer
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now